<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/209426CC-1A50-4F4F-AB89-BEA2A928427A"><gtr:id>209426CC-1A50-4F4F-AB89-BEA2A928427A</gtr:id><gtr:name>Amorfix Life Sciences Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E68501E9-4C3B-4A78-B85D-88EF2B577390"><gtr:id>E68501E9-4C3B-4A78-B85D-88EF2B577390</gtr:id><gtr:name>University of California, San Francisco</gtr:name><gtr:address><gtr:line1>50 Beale Street</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/209426CC-1A50-4F4F-AB89-BEA2A928427A"><gtr:id>209426CC-1A50-4F4F-AB89-BEA2A928427A</gtr:id><gtr:name>Amorfix Life Sciences Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EB4A4021-9A30-4BD4-BBF8-B87C88EC64AB"><gtr:id>EB4A4021-9A30-4BD4-BBF8-B87C88EC64AB</gtr:id><gtr:firstName>Ilaria</gtr:firstName><gtr:surname>Bellantuono</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CDF99109-6551-4702-82BE-688365A28487"><gtr:id>CDF99109-6551-4702-82BE-688365A28487</gtr:id><gtr:firstName>Harry</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Moore</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/09B58C09-565A-4566-BF62-B0749628018E"><gtr:id>09B58C09-565A-4566-BF62-B0749628018E</gtr:id><gtr:firstName>Beining</gtr:firstName><gtr:surname>Chen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8CD1B7E2-1334-4C4F-9501-7800CCA18B87"><gtr:id>8CD1B7E2-1334-4C4F-9501-7800CCA18B87</gtr:id><gtr:firstName>Peter Walter</gtr:firstName><gtr:surname>Andrews</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE014119%2F1"><gtr:id>F535D2F9-AB65-4170-9478-427E48EF26FB</gtr:id><gtr:title>Evaluation and further development of small molecule probes to study the role of prion protein in the ageing and renewal of stem cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E014119/1</gtr:grantReference><gtr:abstractText>Stem cells are particular types of cells that have unique power in regenerating themselves (self-renewal) and developing into other cell types capable of carrying out special tasks in the body. Therefore, stem cells have the potential to change the face of disease treatment by being used to repair specific tissues or to grow organs as regenerative or reparative medicine. However, stem cell research has been at the center of debate for because the majority of current research involves the use of embryonic stem cells. Embryonic stem (ES) cells used in the research are from early stage human embryos. The destruction of a human embryo is usually required in order to start a stem cell 'line'. This poses great ethical concerns and the work in this field has to be vigorously regulated. Although these cells are easy to grow in the laboratory; technical hurdles such as the availability of embryos, methods for producing particular types of tissues and organs from ES cells for intended medical use and the possibility of their rejection by the recipient because they are from different donors, further complicate the research. An alternative to ES cells is the use of adult stem cells. They can be found in the different tissues of the body, undergo self-renewal and can develop into other cell types. They have an advantage that they can be obtained from the patient's own tissue, therefore avoiding the ethical issues and problem of rejection by the immune system. Some type of adult stem cells such as haemopoietic stem (HS) cells, are already being used routinely in bone marrow transplantations. However they exist in very small numbers and this number decreases with the age of the donor. In addition, attempts to isolate and grow most adult stem cells in the laboratory have failed because they age rapidly and the ability of developing into different tissues is lost outside living environments. Therefore the main technical challenges for scientists working in this field lie in isolating them from many other cells, being able to keep them growing and reproducing without aging and maintaining their ability of development in the laboratory. The use of adult stem cells in regenerative medicine can take off rapidly once these problems are overcome. Recent studies have shown that prion proteins, which are connected with a family of deadly neurodegenerative diseases called transmissible spongiform encephalopathies (TSEs) or prion diseases (such as scrapie in goats and sheep, mad cow disease in cattle and vCJD in human) are also present in abundance on the surface of stem cells. It has been shown that in HS cells they help the renewal of these cells. This proposal aims to tackle the problem of aging and renewal in stem cell research. This will be achieved by probing the function of cellular prion protein (PrPC) on the surface of embryonal carcinoma(EC), embryonic stem (ES) cells, and adult mesenchymal stem (MS) cells, using optimised small molecule binders. EC cells will be used in initial high throughput screening to see the effects of 224 binders discovered in the applicants' group on the growth of the stem cells in general, followed by confirmation using ES cells. The active binders will then be further optimised to give rise to some high affinity binders and selected binders will be studied for their ageing and renewal in MS cells, which can potentially differentiate into bones and cartilage to be used as regenerative medicines.</gtr:abstractText><gtr:technicalSummary>Stem cells can divide and renew themselves (self-renewal) whilst retaining the ability to differentiate into other cell types. Therefore, they have the potential to change the face of disease treatment by being used to repair specific tissues or to grow organs as regenerative or reparative medicine. Much research has been devoted to the study of adult stem cells as regenerative medicines as they can be obtained from the patient's own tissue, avoiding the ethical issues and problem of rejection by the immune system. However they exist in very small numbers and this number decreases with the age of the donor. Isolating them, keeping them renewing without aging in culture and retaining their differentiation ability remain a key technical challenge. Cellular prion proteins (PrPC) have been the subject of many intensive studies over more than a decade due to their connections with a family of deadly neurodegenerative diseases called transmissible spongiform encephalopathies (TSEs). Recently, it has been found that PrPC is expressed on haemopoietic stem (HS) cells and to have a role in their self-renewal. It is also suggested that PrPC may be involved in prevention of cellular ageing by preventing accumulation of defective mitochondria. This proposal aims to tackle the problem of aging and renewal in stem cell research. This will be achieved by probing the PrPC on the surface of embryonic carcinoma (EC), embryonic stem (ES) cells and mesenchymal stem(MS) cells using optimised small molecule binders. EC cells will be used in initial high throughput screening to see the effects of 224 binders discovered in the applicants' group on the growth of the stem cells in general followed by confirmation using ES cells. The initial binders will be further optimised to give rise to some high affinity binders and selected binders will be studied for their ageing and renewal in MS cells.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>630740</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of California, San Francisco</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Assessment of DMPK properties of small molecule antiprion compounds in mice models</gtr:description><gtr:id>0E71D822-B85A-4006-9B3F-8620DC47883C</gtr:id><gtr:impact>Results to be published</gtr:impact><gtr:outcomeId>5890a6954e8167.07037378-1</gtr:outcomeId><gtr:partnerContribution>Assessment of DMPK properties of small molecule antiprion compounds in mice models</gtr:partnerContribution><gtr:piContribution>Preparation of small molecule antiprion compounds</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:department>Faculty of Veterinary Medicine</gtr:department><gtr:description>small molecules that influence Prnp expression and differentiation potential of canine BM-MSCs</gtr:description><gtr:id>CDD8B18B-25C4-4457-B1A9-361DE7737F7B</gtr:id><gtr:impact>Results to be published.</gtr:impact><gtr:outcomeId>5890a1da5051b5.92669075-1</gtr:outcomeId><gtr:partnerContribution>Test the small molecules in canine BM-MSCs.</gtr:partnerContribution><gtr:piContribution>Proof of concept validation of small molecules that influence Prnp expression and differentiation potential of canine BM-MSCs.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Investigate the role of prion protein in Alzheimner's disease</gtr:description><gtr:id>AEA66D42-44B5-409E-8430-C98BCFDD3725</gtr:id><gtr:impact>successful studentship and EU grants</gtr:impact><gtr:outcomeId>5890ac32a6e260.93609028-1</gtr:outcomeId><gtr:partnerContribution>Strong track record in drug discovery in commercial sector</gtr:partnerContribution><gtr:piContribution>know-how and 12 years experience in prion research field</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amorfix Life Sciences Ltd</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Test and validation of the role of prion protein in Alzheimer's disease models</gtr:description><gtr:id>6BCC2DCB-6312-4419-986A-31F5821E7F88</gtr:id><gtr:impact>A successful application of EU project</gtr:impact><gtr:outcomeId>5890aa9f653ce1.53600868-1</gtr:outcomeId><gtr:partnerContribution>Production of anti Abeta amyloid antibody</gtr:partnerContribution><gtr:piContribution>Design the epitope of antibody for Abeta amyloid protein</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>8th International Symposium  for Chinese Medicinal Chemists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2E17FF26-A5BE-4A91-A04F-B46AC7AFEB82</gtr:id><gtr:impact>International conference.</gtr:impact><gtr:outcomeId>58909fa60834c6.69350729</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>prion 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B4E403B8-6714-4D19-86F4-FA4ACFBA4292</gtr:id><gtr:impact>Raise public awareness and share scientific information</gtr:impact><gtr:outcomeId>58932fb3cb47c6.68384594</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prion 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A297D425-280F-41DB-A051-3B8A9C6FF64B</gtr:id><gtr:impact>Raise public awareness and share scientific information.</gtr:impact><gtr:outcomeId>58932f5ae8d6e6.84360835</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>9th IUPAC International Symposium on Biomolecular Chemistry</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3D9A29D9-AA7D-435C-9BE8-254963746E8E</gtr:id><gtr:impact>International conference.</gtr:impact><gtr:outcomeId>58909eedd81d96.40267707</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>prion chemical biology article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CC7D5C08-88A2-4EE9-B8E6-A5ABE45F464F</gtr:id><gtr:impact>Raise public awareness</gtr:impact><gtr:outcomeId>589330c70e4211.20244264</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society of Chemistry Biological and Medicinal Chemistry Sector (BMCS) 2nd RSC Symposium on Chemical Biology for Drug Discovery 20th -21st of March 2012 AstraZeneca, Alderley Park, Macclesfield, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1BC0EE41-2776-42D6-8828-8CC81B994EC7</gtr:id><gtr:impact>Raise public awareness in stem cell, the role of prion protein and regenerative medicine.</gtr:impact><gtr:outcomeId>58931858c90b46.15615334</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>101000</gtr:amountPounds><gtr:country>Spain, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Department of Health</gtr:department><gtr:description>Optimisation And Further Biological Evaluation Of Novel Broad Spectrum Antibiotics</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Government of Catalonia</gtr:fundingOrg><gtr:id>2E45769A-D690-4B9B-8D33-B4A1D373FD24</gtr:id><gtr:outcomeId>58877784edc287.18376806</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120576</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>De Novo Design Tool</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Cambridge Crystallographic Data Centre (CCDC)</gtr:fundingOrg><gtr:id>816432A2-0157-4C07-ADF0-F1DD61E84EC3</gtr:id><gtr:outcomeId>588244b2d826c1.36599350</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>192000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Design and Synthesis of Pharmaceutically Relevant Chemical Entities</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:fundingRef>007548</gtr:fundingRef><gtr:id>0595E916-E136-4511-9995-06E096466B2D</gtr:id><gtr:outcomeId>588777106a4cc5.11049777</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>153000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Assessment of the Fanconi Anaemia pathway and its inhibition in Glioblatoma Multiforme</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>DA1C0194-65E5-4DFD-B91B-B7FAE3C1C2F7</gtr:id><gtr:outcomeId>588777ce555a81.63046550</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2209000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Diagnostic and Drug Discovery Initiative for Alzheimer's Disease (D3i4AD)</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>612347</gtr:fundingRef><gtr:id>AC5025CF-7895-4B28-B1BC-9EAA9FCFA76E</gtr:id><gtr:outcomeId>5887787b022a73.85944255</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Weston Park Hospital Cancer Charity</gtr:department><gtr:description>Assessment of the Fanconi Anaemia pathway and its inhibition in Glioblatoma Multiforme</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Weston Park Hospital</gtr:fundingOrg><gtr:id>01AE774F-0521-4A42-8786-66BF9168819F</gtr:id><gtr:outcomeId>5887781fd971f9.81556500</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>224055</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Stem Cell, Prion Protein, and Azlheimer's Disease: A Prion Chemical Biology Network (PCBNet)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>F16FA40F-EBBA-46F0-87E7-87EA0E44DEFC</gtr:id><gtr:outcomeId>58824a2bd557d7.21891992</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>191696</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Design and Synthesis of Pharmaceutically Relevant Chemical Entities</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:id>45C331D4-E464-4E8F-8A5B-214DD4C21E27</gtr:id><gtr:outcomeId>5882495f8cec55.32236968</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings have been used by applicants and others for further research and funding applications.</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>7E32B852-0A46-4028-AE3C-6684A94515BD</gtr:id><gtr:impactTypes><gtr:impactType>Societal</gtr:impactType></gtr:impactTypes><gtr:outcomeId>58c81cc09b1a33.26051498</gtr:outcomeId><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Small molecules that can be used to treat prion and other neurodegenerative diseases and cancer</gtr:description><gtr:grantRef>BB/E014119/1</gtr:grantRef><gtr:id>58B502D3-D531-4A41-BF68-6420EDA2340B</gtr:id><gtr:impact>Novel antiprion therapeutics.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5893494dacc248.89276119</gtr:outcomeId><gtr:patentId>WO090382 A1</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Thiazole and oxazole derivative for use in treatment of prion diseases, cancer and central nervous diseases as well as regulation of stem cells</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Small molecules that stimulate stem cell proliferation</gtr:description><gtr:grantRef>BB/E014119/1</gtr:grantRef><gtr:id>BBE03626-C9F0-41B4-8381-C660948E4A8F</gtr:id><gtr:impact>Novel indole compounds as regenerative medicine.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58934a3c4d1918.69192501</gtr:outcomeId><gtr:patentId>WO 2010/139982 A1</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Novel indole derivatives for stimulating stem cell proliferation</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Cellular protein, PrPC, is required to keep bone marrow MSC in proliferating state and small molecule indole compound, 689, can enhance the proliferation of MSC, more profound when they are in aged state via regulating the SOD2 activities. The MSC cultured in the presence of 689 can increase the bone mass and quality in Osteophorisis mice model.</gtr:description><gtr:exploitationPathways>The findings were published and cited by others working in the field. They were also taken forward by the applicants as bases in the further grant applications.</gtr:exploitationPathways><gtr:id>F24CCA58-EA0E-4045-8637-866F0E749985</gtr:id><gtr:outcomeId>58c81aeadc7e57.85978684</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>EPSRC Theme Day</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>001B1158-ED58-446B-8451-BF5BC040E178</gtr:id><gtr:impact>The recommendation of the theme day reshaped the RU policy and priority on healthcare, especially in regenerative medicine field.</gtr:impact><gtr:outcomeId>589315cde5f110.06118795</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>It contains chemical compounds synthesised in my group.</gtr:description><gtr:id>FD85A472-9EE5-45E8-BF93-A34BC0C932F0</gtr:id><gtr:impact>It has potential to be developed as novel therapeutics.</gtr:impact><gtr:outcomeId>589343d1900f35.06910108</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Chemical compound library</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Small molecules that can enhance the proliferation of stem cells</gtr:description><gtr:id>BF3360E1-F39B-4BEA-BBDA-539470A824D9</gtr:id><gtr:impact>The compounds are available to research community interested</gtr:impact><gtr:outcomeId>589333d79beaf7.27270346</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Small molecule chemical probes</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>It was made available to research groups interested.</gtr:description><gtr:id>E21BA640-11DF-4F42-97C9-23760C987811</gtr:id><gtr:impact>It provides a tool to assess the antiprion activity of compounds.</gtr:impact><gtr:outcomeId>58933bf43ea3f9.85890822</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>SMB cell line</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D25295F3-2097-483E-AAD1-14783D8F41C3</gtr:id><gtr:title>Ugi reactions with ammonia offer rapid access to a wide range of 5-aminothiazole and oxazole derivatives.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e4834f3e9d55cf47db288a6d7f493d2"><gtr:id>7e4834f3e9d55cf47db288a6d7f493d2</gtr:id><gtr:otherNames>Thompson MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>56758c57b37cc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>877940C2-1EE9-4558-AA3A-911CD9F709BB</gtr:id><gtr:title>Synthesis and evaluation of a focused library of pyridine dicarbonitriles against prion disease.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7a50df1707c12d78b91e51dc7ba2b19"><gtr:id>a7a50df1707c12d78b91e51dc7ba2b19</gtr:id><gtr:otherNames>Guo K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>58c873c492e4a0.92966116</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5DC2F64-420F-4153-A09B-D8198631F619</gtr:id><gtr:title>Library synthesis and screening: 2,4-diphenylthiazoles and 2,4-diphenyloxazoles as potential novel prion disease therapeutics.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/362747b94614ee748599744354d39506"><gtr:id>362747b94614ee748599744354d39506</gtr:id><gtr:otherNames>Heal W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>58c87419c93c27.35339461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9457527D-5116-47DA-995A-B38EDBCDADBA</gtr:id><gtr:title>Combination Rules for Group Fusion in Similarity-Based Virtual Screening.</gtr:title><gtr:parentPublicationTitle>Molecular informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68f50a7040c80687a2bcb087cb28a1f9"><gtr:id>68f50a7040c80687a2bcb087cb28a1f9</gtr:id><gtr:otherNames>Chen B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1868-1743</gtr:issn><gtr:outcomeId>58823e1e20c571.08224320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFD8C717-5E45-494E-8684-D7B38F775E95</gtr:id><gtr:title>Evaluation of a Bayesian inference network for ligand-based virtual screening.</gtr:title><gtr:parentPublicationTitle>Journal of cheminformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68f50a7040c80687a2bcb087cb28a1f9"><gtr:id>68f50a7040c80687a2bcb087cb28a1f9</gtr:id><gtr:otherNames>Chen B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1758-2946</gtr:issn><gtr:outcomeId>58823fda0b5f03.65713860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC0C6382-1D5E-4BD6-8995-0C9539423F69</gtr:id><gtr:title>Exploring catalyst and solvent effects in the multicomponent synthesis of pyridine-3,5-dicarbonitriles.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7a50df1707c12d78b91e51dc7ba2b19"><gtr:id>a7a50df1707c12d78b91e51dc7ba2b19</gtr:id><gtr:otherNames>Guo K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>56758c46cdb55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84BCA803-2822-4622-BBB1-1DD1A52F271F</gtr:id><gtr:title>Design, synthesis, and structure-activity relationship of indole-3-glyoxylamide libraries possessing highly potent activity in a cell line model of prion disease.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e4834f3e9d55cf47db288a6d7f493d2"><gtr:id>7e4834f3e9d55cf47db288a6d7f493d2</gtr:id><gtr:otherNames>Thompson MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>56758c8c8e3e1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A821E2B0-8FE9-4D8A-BCAA-D049CD1EAA34</gtr:id><gtr:title>A small molecule modulator of prion protein increases human mesenchymal stem cell lifespan, ex vivo expansion, and engraftment to bone marrow in NOD/SCID mice.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/866aeb2eb2f67561d4badd8e4fd0cf53"><gtr:id>866aeb2eb2f67561d4badd8e4fd0cf53</gtr:id><gtr:otherNames>Mohanty ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>5675d69fb9bbb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAC78AFD-2A94-4E6C-BE5C-AC4A7FEE7130</gtr:id><gtr:title>Improved 2,4-diarylthiazole-based antiprion agents: switching the sense of the amide group at C5 leads to an increase in potency.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e4834f3e9d55cf47db288a6d7f493d2"><gtr:id>7e4834f3e9d55cf47db288a6d7f493d2</gtr:id><gtr:otherNames>Thompson MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn><gtr:outcomeId>58823db44e4977.74015071</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67522CEF-10E0-4F41-974F-7E5F39F54BF7</gtr:id><gtr:title>Ligand-based virtual screening using Bayesian networks.</gtr:title><gtr:parentPublicationTitle>Journal of chemical information and modeling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b5ae32efc1ecfca930facfcd4480f0c"><gtr:id>4b5ae32efc1ecfca930facfcd4480f0c</gtr:id><gtr:otherNames>Abdo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1549-9596</gtr:issn><gtr:outcomeId>58823e741db276.89633528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C20CC343-C447-4BED-B3C9-BEB6C369D3FC</gtr:id><gtr:title>Development of a diversity-oriented approach to oxazole-5-amide libraries.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e4834f3e9d55cf47db288a6d7f493d2"><gtr:id>7e4834f3e9d55cf47db288a6d7f493d2</gtr:id><gtr:otherNames>Thompson MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>56758bd6487d1</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E014119/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>